44 citations
,
April 2015 in “Journal of the American Academy of Dermatology” Combining diphenylcyclopropenone with anthralin is more effective for hair regrowth in alopecia areata than using diphenylcyclopropenone alone, but may cause more side effects.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
December 2023 in “Dermatology and therapy” Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.
20 citations
,
December 2005 in “Journal of Investigative Dermatology Symposium Proceedings” IFN-γ and IL-2 are important for T cell activation in hair loss in mice.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
11 citations
,
January 2022 in “Journal der Deutschen Dermatologischen Gesellschaft” Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.
10 citations
,
February 2023 in “Journal of the European Academy of Dermatology and Venereology” Alopecia areata greatly affects people's life quality, mental health, and work life.
2 citations
,
April 2023 in “Journal of the American Academy of Dermatology” Hispanic/Latinx patients with alopecia areata often have it before age 40, with females and certain health conditions like rheumatoid arthritis more commonly affected.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
January 2023 in “Indian Dermatology Online Journal” Bimatoprost and clobetasol are both effective for scalp hair loss, but bimatoprost works faster, has fewer side effects, and grows more colored hair.
March 2022 in “Wound practice & research” New treatments for alopecia areata show promise, but standardized guidelines are needed.
30 citations
,
September 2020 in “Journal of Patient-Reported Outcomes” Alopecia Areata (AA) causes significant emotional distress, including feelings of embarrassment, depression, and anxiety, and impacts social interactions and daily activities.
23 citations
,
March 2021 in “Dermatologic therapy” Some treatments like pentoxifylline with topical corticosteroids might work for alopecia areata, but more research is needed to find the best one.
14 citations
,
April 2017 in “Dermatology practical & conceptual” Yellow dots are common in severe alopecia areata.
10 citations
,
January 2021 in “Annals of dermatology/Annals of Dermatology” Nivolumab can cause hair loss as a rare side effect.
2 citations
,
November 2022 in “JAAD case reports” COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.
1 citations
,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
1 citations
,
November 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.
December 2023 in “Journal of dermatology” Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.
October 2023 in “Skin health and disease” Alopecia areata costs individuals about 3% of their income, with women, Asians, those with lower income, and more severe symptoms spending more.
July 2023 in “Journal of managed care & specialty pharmacy” Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
February 2023 in “Journal of Cosmetic Dermatology”
4 citations
,
March 2022 in “Dermatology and Therapy” People with moderate hair loss from Alopecia Areata feel more impacted than those with no or almost complete hair loss, and are more likely to seek treatment.
2 citations
,
July 2022 in “Journal of The American Academy of Dermatology” People with alopecia who are more resilient tend to feel less stressed.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
2 citations
,
June 2023 in “Indian journal of dermatology, venereology, and leprology” Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
1 citations
,
February 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
June 2024 in “Frontiers in immunology” Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.